Neutrophils, an important component of the innate immune system, release 20 extracellular traps (NETs) to eliminate invaded pathogens by trapping and killing 21 microbes. A dysfunctional innate immune response is a major cause of persistent 22 hepatitis B virus (HBV) infection. HBV has been shown to reduce neutrophil 23 responses. The objectives of the present study were to determine whether HBV 24 influenced NETs release and to identify the underlying mechanisms. Primary 25 neutrophils and circulating blood samples were collected from 40 patients with a 26 chronic hepatitis B infection (CHB) and 40 healthy controls to detect NETs release 27 using a Quant-iT Pico Green dsDNA assay and to determine the levels of HBV-DNA 28 and HBV markers. NETs release was decreased in patients with a CHB infection, and 29 hepatitis B surface antigen, hepatitis B e antigen and hepatitis B core antibody levels 30 negatively correlated with NETs release. The Quant-iT Pico Green dsDNA assay and 31 western blotting were used to examine the effect of HBV proteins (HBV X protein, 32 HBV C protein, HBV E protein and HBV S protein) on NETs release in vitro. Based 33 on the flow cytometry and western blot data, HBV C protein and HBV E protein
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added and incubated for an additional 30 min at 37°C in the dark. The mean cellular 140 fluorescence intensity was quantified by fluorescence-activated cell sorting analysis.
141
Autophagy detection 142 Autophagy activity was detected by examining the levels of the LC3 and 143 SQSTM1/P62 proteins using western blot analysis. Neutrophils (2×10 6 cells/ml) were 144 incubated with HBV proteins and then stimulated with fMLP (1 μM). Subsequently, 145 we collected cells and extracted proteins to perform western blots.
146
Inhibitor studies 147 For analyses of signalling pathways, neutrophils were preincubated with 148 inhibitors or DMSO for 30 min at 37°C. Rapamycin (mTOR inhibitor, CST) was 149 freshly prepared for each experiment. The data presented here were collected from a minimum of three independent 163 experiments with neutrophils isolated from different blood donors. The results are 164 presented as means±S.D. Statistical analyses were performed with SPSS software 165 version 23. Student's t test was used to compare differences between two groups, and 166 correlations between the quantitative data from two groups were analysed with 167 Pearson's correlation tests. A P-value ≤0.05 was considered statistically significant. 170 We assessed the isolated neutrophils of 40 patients with a CHB infection and 40 171 healthy controls to determine whether NETs release was suppressed in patients with a 172 CHB infection. We used both the original values for cf-DNA/NETs and the 173 cf-DNA/NETs-dsDNA ratio (fMLP-stimulated to unstimulated cells) to express the 174 NETs release ability. As shown in Fig. 1A , the average dsDNA level in patients with a 175 CHB infection (1552±160.9) was less than the level in healthy controls (2152±239.4), 176 and these results were similar to the findings for the NETs-dsDNA ratio (P<0.05) ( Fig.   177 1B). Based on these data, NETs release activity is suppressed in patients with a CHB 178 infection, and HBV may inhibit NETs release.
168

Results
169
Decreased cf-DNA/NETs release in patients with a CHB infection
179
Correlations between serum levels of HBV markers and NETs
180
Serum levels of HBV antigens have been used in the clinic as an index of viral 181 replication, infectivity, disease severity, and the treatment response. We determined 182 the serum levels of HBV markers and HBV-DNA load in patients with a CHB 183 infection to further elucidate the relationship between HBV and NETs. Then, we 184 used a correlation analysis to determine the relationships between serum levels of 185 HBV markers and NETs release activity. As shown in Table 1 , the NETs ratio 186 negatively correlated with HBsAg, HBeAg, and HBcAb levels, but no obvious 187 correlation was observed with HBeAb and HbsAb levels. Moreover, the analysis of 188 the correlations between the NETs ratio and HBV-DNA load did not reveal a 189 significant correlation (Table 2) . Thus, HBV proteins exert a complicated effect on NETs release, and different proteins have different functions.
191
The HBc and HBe proteins inhibit NETs release by suppressing ROS production 192 and autophagy 193 We cultured neutrophils from healthy people with HBs, HBx, HBc, and HBe 194 proteins and PBS to further characterise the effects of HBV proteins on NETs release.
195
After cells were stimulated with fMLP, we measured the levels of the following and HBx proteins had no effect. The western blots for H3 and NE also confirmed 200 these findings (Fig. 1D) . 201 We treated neutrophils from healthy people with CM-H2DCFDA after co-culture 202 with HBV proteins and fMLP stimulation to determine if the diminished ROS 203 production induced by HBV proteins directly inhibited NETs release. Since ROS were 204 produced at high levels in each group, we used the median value to represent ROS 205 production. According to the flow cytometry data, the HBc protein and HBe protein 206 reduced ROS production in neutrophils ( Fig. 2A) , but the HBx protein and HBs 207 protein did not exert significant effects. release, which may be one mechanism by which HBV evades the immune system. and HBe proteins activated the mTOR signalling pathway, as evidenced by the 231 increased levels of phosphorylated mTOR and ULK1 ( Fig. 3B) . Furthermore, we 232 detected the levels of p-P70S6K, a protein downstream of mTOR, and observed 233 increased levels of this protein (Fig. 4B ). Based on these data, the HBc and HBe 234 proteins may enhance the activity of the mTOR pathway and subsequently inhibit 235 NETs release. 236 We used the specific mTOR inhibitor rapamycin in PMNs cultured in the 237 presence of HBc or HBe proteins to confirm the role of the mTOR pathway in the 238 inhibitor effects of the HBc and HBe proteins on NETs release. As expected, 239 rapamycin decreased p-mTOR levels, whereas total mTOR levels remained the same 240 ( Fig. 4B) . Treatment with rapamycin increased H3 expression and cf-DNA/NETs 241 levels (Fig. 4A, Fig. 4C ), suggesting that decreased activation of the mTOR pathway 242 is required for NETs release. HBeAg-negative CHB and controls(46).
326
In summary, HBV inhibits NETs release to escape being trapped and killed.
327
Furthermore, HBV may reduce the responses of neutrophils, which play important 328 roles in innate immunity and inflammation. These changes may be a mechanism by 329 which HBV escapes the immune system. HBV may delay viral clearance and 330 eventually facilitate the establishment of persistent infection in this manner. 
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